Department of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, Tokyo, 143-8540, Japan.
J Infect Chemother. 2013 Aug;19(4):683-90. doi: 10.1007/s10156-012-0544-y. Epub 2013 Jan 25.
Lipopolysaccharide (LPS) is a major contributing factor to endotoxic shock. Colistin specifically binds to LPS. However, it has the disadvantages that adverse reactions are common and it has a short half-life. To overcome these disadvantages, we prepared slow-releasing colistin microspheres and examined the efficacy of these colistin microspheres in a mouse model of endotoxin-induced sepsis. We prepared the colistin microspheres using poly-lactic-co-glycolic acid. For acute toxicity investigations, mice were overdosed with colistin sulfate or colistin microspheres. The group administered with colistin microspheres was associated with less acute toxicity and fewer nephrotoxic changes on histopathological examination compared to the group administered with colistin sulfate alone. For pharmacokinetic analysis, mice were subcutaneously administered with colistin microspheres or colistin sulfate alone. The plasma concentration of colistin was higher in the colistin microspheres group than in the colistin sulfate group at 12 and 24 h after administration. Moreover, mice were intraperitoneally injected with LPS and then immediately subcutaneously administered with blank microspheres, colistin microspheres or colistin sulfate alone. The levels of endotoxin in the sera and cytokine in the spleens were then measured. A significant reduction in the serum endotoxin level in the colistin microspheres group was observed at 24 h. The reduced endotoxin levels in the sera were correlated with the lower cytokine levels in the spleens of mice treated with colistin microspheres. Our results suggest that the use of colistin microspheres may help to maintain a higher colistin concentration in blood, reduce the levels of endotoxin and cytokines in endotoxin-induced sepsis, and lead to decreased toxicity.
脂多糖(LPS)是内毒素性休克的主要致病因素。多粘菌素特异性结合 LPS。然而,它具有不良反应常见和半衰期短的缺点。为了克服这些缺点,我们制备了缓释多粘菌素微球,并在脂多糖诱导的脓毒症小鼠模型中研究了这些多粘菌素微球的疗效。我们使用聚乳酸-共-羟基乙酸制备了多粘菌素微球。为了进行急性毒性研究,用硫酸多粘菌素或多粘菌素微球对小鼠进行了过量给药。与单独给予硫酸多粘菌素相比,给予多粘菌素微球的组在组织病理学检查中具有较少的急性毒性和较少的肾毒性改变。进行药代动力学分析时,单独皮下给予多粘菌素微球或硫酸多粘菌素。与硫酸多粘菌素组相比,多粘菌素微球组在给药后 12 和 24 小时时多粘菌素的血浆浓度更高。此外,用 LPS 腹腔注射小鼠,然后立即皮下给予空白微球、多粘菌素微球或硫酸多粘菌素单独。然后测量血清中的内毒素水平和脾脏中的细胞因子水平。在多粘菌素微球组中,在 24 小时时观察到血清内毒素水平显著降低。血清内毒素水平降低与用多粘菌素微球治疗的小鼠脾脏中细胞因子水平降低相关。我们的结果表明,使用多粘菌素微球可能有助于维持血液中较高的多粘菌素浓度,降低内毒素性脓毒症中内毒素和细胞因子的水平,并降低毒性。